Logo.png
QHSLab Announces Impressive 2023 Fiscal Year Results with Growing Revenues, Improved Gross Margins, and Substantial Reduction in Net Loss
28 mars 2024 08h00 HE | QHSLab, Inc.
WEST PALM BEACH, FL, March 28, 2024 (GLOBE NEWSWIRE) -- QHSLab, Inc. (the “Company”) (OTCQB: USAQ), a company focused on providing clinicians with tools to leverage proactive, value-based healthcare...
Acrivon logo.jpg
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
28 mars 2024 08h00 HE | Acrivon Therapeutics, Inc
WATERTOWN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
Logo.png
IMUNON Reports 2023 Financial Results and Provides Business Update
28 mars 2024 08h00 HE | Imunon, Inc.
Conference Call Begins Today at 10:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on...
indaptus_logo.png
Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference
28 mars 2024 08h00 HE | Indaptus Therapeutics
NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection...
Sagimet-Logo-for-light-bg-FIN.png
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
27 mars 2024 16h01 HE | Sagimet Biosciences Inc.
SAN MATEO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN)...
Erasca_Logo_FullColor_RGB.jpg
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
27 mars 2024 16h01 HE | Erasca, Inc.
Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts expected in 2024 for naporafenib...
Celcuity+Logo.jpg
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
27 mars 2024 16h01 HE | Celcuity Inc.
Dosed the first patient in a Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for the treatment of metastatic castration resistant prostate cancer Presented nonclinical data...
Inventiva reports it
Inventiva reports its 2023 full-year results
27 mars 2024 16h00 HE | INVENTIVA
Revenues at €17.5 million for the full year of 2023 up 43.4% compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million, short-term deposits at €0.01 million1, and long-term deposit...
Molecular Diagnostics Market
Global Molecular Biosensors Market Demonstrates Impressive Growth with Expanding Applications in Healthcare and Environmental Monitoring
27 mars 2024 15h45 HE | Research and Markets
Dublin, March 27, 2024 (GLOBE NEWSWIRE) -- The "Molecular Biosensors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F" report has been added to ...
Algernon Logo 1.png
Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
27 mars 2024 12h04 HE | Algernon Pharmaceuticals Inc.
VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...